Rubitecan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rubitecan
Rubitecan.svg
Systematic (IUPAC) name
(4S)-4-ethyl-4-hydroxy-11-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Clinical data
Trade names Orathecin
Routes of
administration
Oral (capsules)
Legal status
Legal status
  • Application withdrawn
Pharmacokinetic data
Bioavailability 25–30% (rubitecan and 9-AC; in dogs)
Protein binding 97% (rubitecan), 65% (9-AC)
Metabolism Probably CYP-dependent
Metabolites 9-aminocamtothecin (9-AC)
Biological half-life 15–18 hours (rubitecan), 18–22 hours (9-AC)
Excretion Bile and feces (major proportion), urine (the minor one)[1]
Identifiers
CAS Number 91421-42-0 YesY
ATC code None
PubChem CID 472335
ChemSpider 414807 N
UNII H19C446XXB N
KEGG D04031
ChEBI CHEBI:90225
ChEMBL CHEMBL77305 N
Synonyms (19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Chemical data
Formula C20H15N3O6
Molar mass 393.349 g/mol
 NYesY (what is this?)  (verify)

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.

History[edit]

On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3]

On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[4] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[5]

References[edit]